The study assessed the HIV treatment cascade of people living with HIV (PLWH) in Iran and the reasons for gaps in HIV services in 2014. We did the cascade analysis using the WHO HIV test-treat-retain cascade analysis tool (2014). To measure the gaps, we checked the records for all PLWH reported to the national HIV surveillance till September 2014 to define how many were alive, linked to HIV care, assessed for CD4 cell count, started antiretroviral therapy (ART), and reported to be alive up to five years after ART. To assess the reasons for gaps in the cascade, we ran desk review, four focus group discussions and 51 in-depth interviews with key informants including PLWH. Spectrum model estimated 75,700 PLWH in Iran, of whom only 22,647 people (%30) were diagnosed. Of those who were diagnosed with HIV, 16,266 people (%72) had enrolled in HIV care. About 13% of all PLWH were retained in HIV care and only 9% (6745 people) had ever been tested for CD4 cell count. Only 8% (6018 people) of all PLWH had received ART by September 2014. We found the biggest gap in the HIV treatment cascade to be HIV diagnosis as only 30% of PLWH have been diagnosed. Innovative strategies to improve HIV testing, particularly those that work best for key populations, are critical to reach the 90-90-90 targets.
Introduction
Worldwide, access to antiretroviral therapy (ART) for 15 million HIV-positive people who are not on treatment is one of the ten goals of the universal access program. Shortage in HIV care engagement includes late HIV diagnosis, suboptimal linkage to and retention in HIV care, insufficient use of ART, and suboptimal adherence to therapy, posing significant barriers to achieving optimal treatment outcomes. 1 Coverage of ART in the eastern Mediterranean region, where Iran is located, is less than 14%, the lowest in the world. The huge number of undiagnosed and thus untreated people living with HIV (PLWH) makes the region the only region in the world where the rate of treatment coverage is very low. 2 According to an estimation made by Spectrum modeling in 2014, there are more than 75,000 (uncertainty interval [UI] 49,600 to 135,400) PLWH in Iran. The major driver of the HIV epidemic in Iran is unsafe drug injection, while over recent years, heterosexual transmission has been increasing. 3 In recent years HIV data show a decrease in the male to female ratio with an increase in the rate of heterosexual transmission (8.3 to 2.4 M/F ratio). 3 To assess the HIV program systematically and comprehensively, we need to look at all steps of the HIV treatment cascade from diagnosis to treatment and the effect of the treatment. The "HIV treatment cascade" is a tool to identify strengths and weaknesses of delivery of services to PLWH in the process of the care cascade by closely examining the proportion of PLWH engaged in each of the five separate stages of the HIV care cascade (HIV diagnosis, linkage to HIV care, staying in HIV care, getting ART, and sustaining undetectable viral loads). By using this tool, policy makers and program managers are able to pinpoint where gaps may exist in the services. It also helps to prioritize and target available resources and to monitor national progress in response to HIV. 1 For the first time, our study was carried out to assess the treatment cascade of PLWH in Iran and the reasons for gaps in the HIV treatment cascade by desk review, expert opinion, and key informants' interviews.
Methods
We did the cascade analysis using the WHO HIV testtreat-retain cascade analysis tool (2014). 4 First, a technical working group was developed to lead and conduct the analysis. The technical working group also received technical supports from a steering committee that included key persons working in the field of HIV and key stakeholders. The cascade analysis included quantitative and qualitative methods to measure the gaps and to assess the reasons for such gaps in the HIV treatment cascade.
For the quantitative analysis, we used a Spectrum model to estimate the number of PLWH. Using the national HIV registry system by September 2014, there were 28,663 persons diagnosed with HIV. By linking the patients' data to mortality data, we found and excluded 6016 cases of death. Then, we looked at HIV care data which included visits by physicians, CD4 cell count and medical examination for opportunistic infections by inquiries from health facilities providing services to PLWH. Any person with documented referral (in HIV care data) to a triangular clinic and tested with a confirmatory test was considered to be linked to HIV care, and those who visited the triangular clinic at least twice a year were considered to be retained in care. All PLWH who had a record of ART prescription were considered to have been initiated on ART. UIs in the percentages for each steps of the HIV treatment cascade were estimated based on uncertainty in the number of PLWH. We measured the survival rate at 12, 24 and 60 months after ART in those who started the medication.
To assess the reasons for drop out from the HIV treatment cascade and the status of receiving care and treatment services and related variables for PLWH, we did a cross-sectional study with questionnaire-based interviews with HIV experts and also among 273 PLWH enrolled in care across the country (174 on ART and 99 eligible for ART but not on treatment). The qualitative analysis included focus group discussions (FGDs) 5 and in-depth interviews with 18 policy makers 6 and 51 health officers dedicated to local HIV program at triangular, Drop-in Centers (DIC) and Methadone Maintenance Treatment (MMT) centers. 7 We had two FGDs with health care workers at triangular clinics and, and two FGDs with those health workers in DIC and MMT centers, and two FGDs with PLWH. Using a guide (with an opening section, and follow-up questions about barriers and facilitators for each of steps in the cascade), one FGD leader probed questions on different steps in the HIV treatment cascade and reasons for the gap and how barriers could be addressed. All FGDs were audio recorded and were transcribed to text files. The FGDs were analyzed by the content analysis: First, the text was reviewed carefully and relevant parts of the text were determined and coded, and then the themes were summarized. We chose the themes based on the barriers reported for each step in the cascade and the potential solutions. Our themes and methodology were chosen based on the WHO guide on HIV test-treat-retain cascade analysis. 4 For coding, we used Microsoft Word Office, Seattle, Washington, USA.
For the in-depth interviews with policy makers and key informants, we used a structured open format questionnaire. We interviewed 18 key informants with expertise in HIV epidemiology and programs, 51 heath care providers from three different cities and 3 PLWH. All interviews were transcribed and analyzed as we described above for FGD data analysis.
Results
About 75,700 (UI 49,600 to 135,400) people were estimated to be living with HIV in 2014 in Iran (Figure 1 (a)). By September 2014, 22,647 people had been diagnosed with HIV, which corresponds to only 30% (UI 17 to 46%) of all PLWH. Of those who were diagnosed with HIV, 16,266 people had enrolled in HIV care. About 13% (UI 7 to 19%) (or 9568 people) of all PLWH were retained in HIV care while only 9% (UI 5 to 14%) (6745 people) had ever been tested for CD4 cell count. Only 8% (UI 4 to 12%) (6018 people) of all PLWH had received ART by September 2014. Survival on treatment at 12, 24, and 60 months after ART was 84.8%, 72.9%, and 55.8% among those who started medication, respectively.
Among those who had been diagnosed with HIV, 72% were in care, 42% retained in care, and only 27% had received ART (Figure 1(b) ).
From September 2013 to September 2014, 113,413 persons were tested for HIV by the public health sector, of whom 112,011 people (98.7%) were given their test results, and of whom, 1404 (1.2%) tested positive. Over the same period, 84.7% (1225 out of 1445) of the patients who started ART were retained for 12 months follow-up.
Reasons for losses in the HIV treatment cascade are presented in Table 1 . As we did not see heterogeneity and major different points of view emerged among key informants, we did not report the qualitative results separately by different key informants. For gaps in HIV diagnosis, several barriers such as existing stigma (particularly within family) for HIV and related risk behaviors, lack of knowledge among key populations on HIV testing and available services, inexperienced health workers in working with key populations, low perception of HIV risk among the key population at risk and lack of motivation and partnership in the private health sector were reported frequently by the key informants. They also provided some recommendations including increasing knowledge and demand for HIV testing, simplifying the HIV diagnosis process, and involvement of the private sector in HIV testing services.
Frequently mentioned barriers for enrollment in HIV care were poor care-seeking in the majority of affected key populations, poor motivation for selfcare in patients because of other priorities, marginalized populations and those living in areas out of public health access, insufficient number of well-trained counselors for counseling, insufficient support for transportation and some specific services. Key informants also provided some recommendations to address the Monitoring adherence program must be clearly defined and implemented in the triangular clinics.
Use of infrastructures and available capacities such as the private sector or family physicians for delivering care and treatment in other districts.
Mental health care should be provided to these patients and their families.
barriers such as recruitment of trained and motivated personnel, people with a positive rapid test result to be linked to HIV services, increase access to mental health services, use of peer group and 'positive club' capacities to establish trust in communication between PLWH and service providers.
For ART initiation and retention in ART, reported barriers included adverse drug reactions or fear of drug interactions with methadone and narcotic drugs, insufficient knowledge about benefits of ART, high pill burden, psychological and mental problems. Participants also provided suggestions for improvement in ART services such as the need to have the supply chain management of anti-retroviral drugs to be improved, fixed dose combinations to be procured in order to have simpler regimens available, a program for monitoring adherence to ART to be defined and implemented carefully in the triangular clinics.
Results of PLWH survey conducted among 273 PLWH enrolled in care across the country (174 on ART and 99 eligible for ART but not on treatment and one of unknown status) are presented in Table 2 . Overall, 217 of the PLWH were male (79.5%) and there was no significant difference between men and women (P-value: 0.3). Majority of PLWH in both groups were 25-44 years old and there was a significant difference between two groups regarding the age groups (P-value: 0.04). A total of 4% of the PLWH were illiterate, but there was a significant difference between the two groups in high school or academic education (P-value: 0.02). Only 17% of PLWH had a permanent job, but there was a significant difference between the two groups regarding the job status (P-value: 0.002). In terms of transmission risk, there was a significant difference in injecting drug use between the two groups (P-value: 0.008). Also between the two groups, there was a significant difference in the explanation in the post-test counseling about ART benefits, ART side effects and dietary regimens (P-value: 0.05, 0.001 and 0.02 respectively). The study showed 35.7% of PLWH were followed up by the referral center and there was no difference between those on ART and not on ART. Survey revealed that 59% of those receiving ART and 69.7% of those not on ART had received some type of supportive services including financial, employment, nutritional, transportation supports as well as health insurance and membership of a 'positive club'. No significant difference has been detected between the two groups. In total, about one-third of the PLWH had a history of not receiving a service due to lack of financial ability and lack of that service in the city. The difference between the two groups was not significant in any of these records. The study showed that 95.1% of PLWH were satisfied by services provided in triangular clinics, and there was no difference between those on ART and not ART.
Discussion
We found that less than one in ten (10%) PLWH in Iran have ever initiated ART up until 2014. The biggest gap in the HIV treatment cascade is HIV diagnosis, as only 30% of PLWH have been diagnosed. The treatment strategy in 2014 which required a CD4 cell count < 500 cells/ml caused a loss of about 16,000 people in the continuum of care after diagnosis. Per updated ART guidelines in Iran, 3 CD4 is no longer needed for ART initiation, and so, we expect that part of the reasons for gaps has already been addressed. We also identified several reasons for losses in the HIV treatment cascade as well as recommendations to improve them.
Our findings showed that to reach 90-90-90 UNAIDS targets, Iran needs to improve diagnosis and linkage to care programs, particularly for the key populations. The 1.2% positivity rate in 2013-2014 was very low, and targeted or index case testing is critical to find the numerous undiagnosed people. Although HIV rapid testing has become available in 1017 health facilities, the usage of such services by members of key populations (such as people who inject drugs) is still low. Only onethird of people who inject drugs tested for HIV in the last year, 8 and only two-thirds of female sex workers in 2015 reported recent HIV testing. 9 The current HIV testing and counseling program in Iran requires people to visit facilities, which, for members of the key populations, is a barrier. Scaling up community-based non-clinical testing programs, 3 offering HIV self-testing 10 and peerdriven HIV testing 11 which have been shown to improve HIV testing in other settings need to be considered to improve such a big gap in diagnosis.
Retention in HIV care also needs to improve in Iran. Studies in the United States for mobile-based interventions among men who have sex with men 12 showed improvement in retention in HIV care. Peer navigation and supports intervention and supports for patient transportation, 13 family centered approaches 14 and the use of lay healthcare providers 15 were all effective strategies to improve retention. All these potential effective models need to be adapted and piloted for Iranian settings.
Since July 2017, Iran adapted and implemented the test and treat strategy for all HIV-diagnosed patients. This strategy may improve part of gap that resulted from the time lag between HIV care and treatment. In Iran, the private sector has a major role in delivering diagnostic and therapy services to people living in urban settings. 16 Educating and working with providers in the private sector is key to improving HIV treatment and also retention of those who are on treatment, if the country has a plan for expansion of HIV services at a district level. Other groups of providers, mostly as lay providers, can help in navigating and supporting PLWH to remain on ART and have a good quality of life. In Iran, many harm reduction and prevention services are being delivered by NGOs. 17 They have successfully reached and provided such prevention services to members of the key populations, mostly those injecting drugs. Involving NGOs in post-ART programs for follow-up and improving retention, and having the NGOs provide support to those on ART as well as in the delivery of the program to address mental health needs to be explored and piloted. The structural barriers including long distances between where people live and where services are and transportation needs to visit the clinics were also mentioned by some key informants. This could be addressed by some stipends for transportation, 18 conditional small cash programs and incentives for those who made their clinic visits on time, 19 which not only improves adherence, but also encourages marginalized populations with low incomes to visit the services more often. 19 Perceived or real stigma has also been reported as one of the barriers for HIV testing and treatment. Educating communities and patients about their rights, 20 normalizing HIV testing by campaigns 21 and by wisely involving partners and families in support groups 14 can reduce the stigma associated with HIV and increase the chance of using the existing services. HIV self-testing has many potentials, 10 but strategies to improve linkage to confirmatory and treatment services after self-testing need to be adapted or developed for Iran and other similar developing settings. Health providers also should be trained 15 and monitored to provide stigma-friendly services and environments welcoming people, in particular, those engaged in stigmatized behaviors like same-sex or transactional sexual contacts or drug injection.
Based on the results of the PLWH survey, about 36% of those not on ART live with their permanent or temporary spouses, which means they do not have the benefits of treatment themselves, and their spouses are also deprived of it. About 96% of PLWH have a minimum level of reading and writing literacy that can be used for writing textbooks for educating them, but 4% of others need special methods for educating illiterate people. The counseling was well discussed regarding ways of transmission and the benefits of ART, but the amount of information provided in the post-test consultation was lower regarding ART side effects, particularly that those not on ART are less likely to benefit from treatment. This can affect patient expectations of treatment and its subsequent adherence.
Our study had three limitations. First, the number of PLWH was estimated by modeling which is subject to model assumptions and uncertainties. Second, adherence to ART and viral load were not measured or reported systematically for people on ART and so, we were not able to assess them. Last, we used all registered HIV case data until 2014 to analyze the overall cascade, which may not reflect the cascade of recently diagnosed patients, or the subgroups defined by demographic characteristics or high-risk behaviors.
Despite the limitations, clearly the biggest gap in the HIV treatment cascade in Iran is the gap in case finding and diagnosis. Innovative strategies to improve HIV testing, particularly those which work best for the key populations, are critical to reach the 90-90-90 targets. Future continuum of care analysis should consider adding viral suppression and ART adherence indicators, and also evaluating the cascade by demographic characteristics and high-risk behaviors. Using the potentials of the private sector and NGOs to deliver HIV services and reducing the stigma in families, communities and health care settings are necessary to scaleup and improve the HIV cascade in Iran. 
